Thalidomide survivor calls on government to boost annual payment
OTTAWA — A Health Canada revamp of a compensation program doesn’t boost annual payments to a level that could make the difference between independence and institutionalization, thalidomide survivor Fiona Sampson said Thursday.
Changes to the federal program announced on Wednesday include an increase to a lump-sum payment for survivors — to $250,000 from $125,000 and an update to eligibility criteria that the Trudeau government acknowledged may have excluded some victims.
Thalidomide was a drug billed as a safe, effective sedative and morning-sickness remedy when it first became available in Canada in 1959 but it was banned in 1962 after it was discovered to be causing widespread birth defects and deaths.
Sampson said Thursday she welcomes Health Canada program reforms but she and a group of survivors are upset the government didn’t also increase annual payments for victims suffering long-term harms from the drug.